222 related articles for article (PubMed ID: 26522053)
1. Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs.
Rasmussen RM; Kurzman ID; Biller BJ; Guth A; Vail DM
Vet Comp Oncol; 2017 Jun; 15(2):421-430. PubMed ID: 26522053
[TBL] [Abstract][Full Text] [Related]
2. Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients.
Denies S; Cicchelero L; de Rooster H; Daminet S; Polis I; Van de Maele I; Sanders NN
Vet Comp Oncol; 2017 Jun; 15(2):594-605. PubMed ID: 26961119
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of toxicities from combined metronomic and maximal-tolerated dose chemotherapy in dogs with osteosarcoma.
Bracha S; Walshaw R; Danton T; Holland S; Ruaux C; Obradovich J
J Small Anim Pract; 2014 Jul; 55(7):369-74. PubMed ID: 24803081
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi-institutional retrospective study of the Italian Society of Veterinary Oncology.
Marconato L; Chalfon C; Finotello R; Polton G; Vasconi ME; Annoni M; Stefanello D; Mesto P; Capitani O; Agnoli C; Amati M; Sabattini S
Vet Comp Oncol; 2019 Dec; 17(4):537-544. PubMed ID: 31251441
[TBL] [Abstract][Full Text] [Related]
5. Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide.
Polton G; Finotello R; Sabattini S; Rossi F; Laganga P; Vasconi ME; Barbanera A; Stiborova K; Rohrer Bley C; Marconato L
Vet Comp Oncol; 2018 Sep; 16(3):399-408. PubMed ID: 29508493
[TBL] [Abstract][Full Text] [Related]
6. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.
Mitchell L; Thamm DH; Biller BJ
J Vet Intern Med; 2012; 26(2):355-62. PubMed ID: 22303814
[TBL] [Abstract][Full Text] [Related]
8. Effects of chemotherapy on immune responses in dogs with cancer.
Walter CU; Biller BJ; Lana SE; Bachand AM; Dow SW
J Vet Intern Med; 2006; 20(2):342-7. PubMed ID: 16594592
[TBL] [Abstract][Full Text] [Related]
9. Toxicity of metronomic cyclophosphamide chemotherapy in a UK population of cancer-bearing dogs: a retrospective study.
Harper A; Blackwood L
J Small Anim Pract; 2017 Apr; 58(4):227-230. PubMed ID: 28133740
[TBL] [Abstract][Full Text] [Related]
10. High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors.
Spugnini EP; Buglioni S; Carocci F; Francesco M; Vincenzi B; Fanciulli M; Fais S
J Transl Med; 2014 Aug; 12():225. PubMed ID: 25143012
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Doxorubicin with or without Metronomic Cyclophosphamide for Canine Splenic Hemangiosarcoma.
Matsuyama A; Poirier VJ; Mantovani F; Foster RA; Mutsaers AJ
J Am Anim Hosp Assoc; 2017; 53(6):304-312. PubMed ID: 28892429
[TBL] [Abstract][Full Text] [Related]
12. Immunological, anti-angiogenic and clinical effects of intratumoral interleukin 12 electrogene therapy combined with metronomic cyclophosphamide in dogs with spontaneous cancer: A pilot study.
Cicchelero L; Denies S; Vanderperren K; Stock E; Van Brantegem L; de Rooster H; Sanders NN
Cancer Lett; 2017 Aug; 400():205-218. PubMed ID: 27693635
[TBL] [Abstract][Full Text] [Related]
13. The addition of metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma.
Alexander CK; Cronin KL; Silver M; Gardner HL; London C
J Small Anim Pract; 2019 Jan; 60(1):32-37. PubMed ID: 30209807
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas.
Mainetti LE; Rico MJ; Fernández-Zenobi MV; Perroud HA; Roggero EA; Rozados VR; Scharovsky OG
Ann Oncol; 2013 Sep; 24(9):2310-6. PubMed ID: 23666914
[TBL] [Abstract][Full Text] [Related]
15. Primary Hepatic Neuroendocrine Carcinoma Treated with Doxorubicin and Cyclophosphamide in a Dog.
Morgan E; O'Connell K; Thomson M; Boyd S; Sandy J
J Am Anim Hosp Assoc; 2019; 55(3):e55305. PubMed ID: 30870605
[No Abstract] [Full Text] [Related]
16. The use of low-dose metronomic chemotherapy in dogs-insight into a modern cancer field.
Gaspar TB; Henriques J; Marconato L; Queiroga FL
Vet Comp Oncol; 2018 Mar; 16(1):2-11. PubMed ID: 28317239
[TBL] [Abstract][Full Text] [Related]
17. Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma.
Burton JH; Mitchell L; Thamm DH; Dow SW; Biller BJ
J Vet Intern Med; 2011; 25(4):920-6. PubMed ID: 21736624
[TBL] [Abstract][Full Text] [Related]
18. Furosemide for prevention of cyclophosphamide-associated sterile haemorrhagic cystitis in dogs receiving metronomic low-dose oral cyclophosphamide.
Setyo L; Ma M; Bunn T; Wyatt K; Wang P
Vet Comp Oncol; 2017 Dec; 15(4):1468-1478. PubMed ID: 28194917
[TBL] [Abstract][Full Text] [Related]
19. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.
Tongu M; Harashima N; Monma H; Inao T; Yamada T; Kawauchi H; Harada M
Cancer Immunol Immunother; 2013 Feb; 62(2):383-91. PubMed ID: 22926062
[TBL] [Abstract][Full Text] [Related]
20. Incidence of sterile hemorrhagic cystitis in tumor-bearing dogs concurrently treated with oral metronomic cyclophosphamide chemotherapy and furosemide: 55 cases (2009-2015).
Chan CM; Frimberger AE; Moore AS
J Am Vet Med Assoc; 2016 Dec; 249(12):1408-1414. PubMed ID: 27901449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
